We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abionyx Pharma | EU:ABNX | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.112 | 8.93% | 1.366 | 1.30 | 1.376 | 1.482 | 1.28 | 1.29 | 526,229 | 16:40:00 |
From Jun 2023 to Jun 2024
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today announces the appointment of Laurent Guerci as Chief Digital & Innovation Officer.
Agricultural engineer and graduate of the CPA (Executive MBA), Laurent Guerci has spent his entire career in information systems, first as the founding director of a company specialized in ERP for agricultural applications, which he sold, then as consulting director in information systems at PWC, and finally as director of various profit centers within the ACTIA industrial Group, where he was in charge of developing new digital activities in France and abroad.
He will be responsible for carrying out various projects to structure ABIONYX Pharma, in particular the digitalisation of the Group. ABIONYX Pharma's ambition, in support of its innovative biotherapies strategy, is to digitalise its internal processes, its exchanges with its pharmaceutical partners and to use its data capital through the use of Artificial Intelligence technologies to improve its know-how in pre-clinical and clinical studies and the development of innovative therapies, whether in sepsis, renal diseases or ophthalmology.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712247349/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas Fossiez abionyx@newcap.eu +33 (0)1 44 71 94 94
NewCap Media relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 94 94
1 Year Abionyx Pharma Chart |
1 Month Abionyx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
